# Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Study · id `cardio:ct-nct06742567` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06742567](<https://clinicaltrials.gov/study/NCT06742567>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06742567

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 472 participants.

## Technical summary

Registry record NCT06742567. Randomized; single masking; primary purpose prevention. Start 2024-12-02 (actual); primary completion 2025-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 472 participants (planned count; ClinicalTrials.gov record NCT06742567, source copy `cardio:ctgov-nct06742567-2024-12-19`, retrieved 2026-10-26)
- Started: 2024-12-02 (actual) (ClinicalTrials.gov record NCT06742567, source copy `cardio:ctgov-nct06742567-2024-12-19`, retrieved 2026-10-26)
- Primary completion: 2025-11-30 (anticipated) (ClinicalTrials.gov record NCT06742567, source copy `cardio:ctgov-nct06742567-2024-12-19`, retrieved 2026-10-26)
- Completion: 2025-11-30 (anticipated) (ClinicalTrials.gov record NCT06742567, source copy `cardio:ctgov-nct06742567-2024-12-19`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT06742567, source copy `cardio:ctgov-nct06742567-2024-12-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06742567-2024-12-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
- Acronym: POTAMI
- Condition: Acute Myocardial Infarction of Anterior Wall
- Condition: Left Ventricular Thrombus
- Condition: Prophylaxis
- Intervention (Drug): Apixaban 2.5 MG PO BID
- Intervention (Drug): Control (Standard treatment)
- Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiovascular Diseases, Pakistan (`cardio:org-national-institute-of-cardiovascular-diseases-pakistan`)

## Provenance

Content hash: 9c5c34c4a624c8c90b91a78fa796020d31bbc63f314c58765b8245c580771130
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
